PsiOxus Therapeutics

U.K. government awards $2.7M grant to PsiOxus cancer vaccine

Wednesday, November 7, 2012 10:57 AM

PsiOxus Therapeutics, a development stage biotechnology company based in the U.K was awarded a $2.7 million grant from the U.K. government-backed Biomedical Catalyst to initiate a phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

More... »

Quest Diagnostics

PsiOxus launches phase I/II trial of oncolytic vaccine in metastatic cancer

Wednesday, September 26, 2012 12:07 PM

PsiOxus Therapeutics, a U.K.-based development stage biotech, has treated the first patient in its phase I/II clinical trial of ColoAd1for the treatment of metastatic solid tumors.

More... »



CWWeekly

April 20

Christie Clinic, PMG Research's 12th clinical research site, expands its geographic reach north to Illinois

Clinipace acquires Accovion to expand European presence, following an infusion of equity that could lead to more deals

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs